UPMC Cancer Center at UPMC Northwest
Claim this profileSummary
UPMC Cancer Center at UPMC Northwest is a medical facility located in Seneca, Pennsylvania. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. UPMC Cancer Center at UPMC Northwest is involved with conducting 98 clinical trials across 221 conditions. There are 21 research doctors associated with this hospital, such as Liza C. Villaruz, Adam Brufsky, MD, Melissa A. Burgess, and Dan P. Zandberg.Area of expertise
Lung Cancer
UPMC Cancer Center at UPMC Northwest has run 26 trials for Lung Cancer. Some of their research focus areas include:
Breast Cancer
UPMC Cancer Center at UPMC Northwest has run 19 trials for Breast Cancer. Some of their research focus areas include:
Top PIs
Liza C. Villaruz
University of Pittsburgh Cancer Institute (UPCI)
6 years of reported clinical research
Adam Brufsky, MD
University of Pittsburgh Cancer Institute (UPCI)
2 years of reported clinical research
Melissa A. Burgess
University of Pittsburgh Cancer Institute (UPCI)
5 years of reported clinical research
Dan P. Zandberg
University of Pittsburgh Cancer Institute (UPCI)
4 years of reported clinical research
Clinical Trials running at UPMC Cancer Center at UPMC Northwest
Lung Cancer
Prostate Cancer
Bladder Cancer
Breast cancer
Non-Small Cell Lung Cancer
Oropharyngeal Carcinoma
Esophageal cancer
Breast Cancer
Prostate Adenocarcinoma
Squamous Cell Carcinoma
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting
2 awards
Phase 3
28 criteria
Cemiplimab
for Non-Small Cell Lung Cancer
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody that stimulates the immune system by blocking the PD-1 pathway. Tumors use the PD-1 pathway to escape attacks from the immune system. By blocking the PD-1 pathway, cemiplimab may help the immune system recognize and attack tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Adding cemiplimab to usual treatment, docetaxel and ramucirumab, may kill more tumor cells compared to docetaxel and ramucirumab alone in treating patients with stage IV or recurrent non-small cell lung cancer.
Recruiting
1 award
Phase 2 & 3
19 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at UPMC Cancer Center at UPMC Northwest?
UPMC Cancer Center at UPMC Northwest is a medical facility located in Seneca, Pennsylvania. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. UPMC Cancer Center at UPMC Northwest is involved with conducting 98 clinical trials across 221 conditions. There are 21 research doctors associated with this hospital, such as Liza C. Villaruz, Adam Brufsky, MD, Melissa A. Burgess, and Dan P. Zandberg.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.